The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas

Journal of Pathology

Volumn 229, Issue 5, 2013, Pages 765-774

  Qian, Dong ^a   Zhang, Bin ^a,b   He, Li Ru ^a   Cai, Mu Yan ^a   Mai, Shi Juan ^a   Liao, Yi Ji ^a   Liu, Yan Hui ^c   Lin, Marie C ^d   Bian, Xiu Wu ^e   Zeng, Yi Xin ^a   Huang, Jun Jian ^f   Kung, Hsiang Fu ^a,d   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

chemoradiotherapy; mitosis catastrophe; oesophageal squamous cell carcinoma; PinX1; telomere dysfunction

Indexed keywords

CISPLATIN; FLUOROURACIL; PINX1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; MITOSIS; RNA INTERFERENCE; SURVIVAL ANALYSIS; TELOMERASE; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875050329     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4163     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al,. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Lin SH, Chang JY,. Esophageal cancer: diagnosis and management. Chin J Cancer 2010; 29: 843-854.
3. Tahara M, Ohtsu A, Hironaka S, et al,. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35: 316-323.
4. Kim NW, Piatyszek MA, Prowse KR, et al,. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
5. Hahn WC, Counter CM, Lundberg AS, et al,. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
6. Asai A, Kiyozuka Y, Yoshida R, et al,. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998; 18: 1465-1472.
7. Mitsui A, Kuwabara Y, Iwase H, et al,. Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent. J Surg Oncol 2002; 79: 37-45.
8. Zhang X, Komaki R, Wang L, et al,. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 2008; 14: 2813-2823.
9. Wong KK, Chang S, Weiler SR, et al,. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing RT. Nature Genet 2000; 26: 85-88.
10. von Figura G, Hartmann D, Song Z, et al,. Role of telomere dysfunction in aging and its detection by biomarkers. J Mol Med (Berl) 2009; 87: 1165-1171.
11. Zhou XZ, Lu KP,. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001; 107: 347-359.
12. Lin J, Jin R, Zhang B, et al,. Characterization of a novel effect of hPinX1 on hTERT nucleolar localization. Biochem Biophys Res Commun 2007; 353: 946-952.
13. Yuan K, Li N, Jiang K, et al,. PinX1 is a novel microtubule-binding protein essential for accurate chromosome segregation. J Biol Chem 2009; 284: 23072-23082.
14. Zhang B, Bai YX, Ma HH, et al,. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res 2009; 69: 75-83.
15. Zhang B, Qian D, Ma HH, et al,. Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation. Oncogene 2012; 31: 1-12.
16. He LR, Liu MZ, Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2010; 127: 138-147.
17. Cai MY, Zhang B, He WP, et al,. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010; 101: 1543-1549.
18. Takai H, Smogorzewska A, de Lange T,. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-1556.
19. Akiyama Y, Maesawa C, Wada K, et al,. Human PinX1, a potent telomerase inhibitor, is not involved in human gastrointestinal tract carcinoma. Oncol Rep 2004; 11: 871-874.
20. Hawkins GA, Chang BL, Zheng SL, et al,. Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 2004; 60: 298-302.
21. Kondo T, Oue N, Mitani Y, et al,. Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 2005; 24: 157-164.
22. Chang Q, Pang JC, Li J, et al,. Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 2004; 109: 309-314.
23. Zhou XZ, Huang P, Shi R, et al,. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest 2011; 121: 1266-1282.
24. Verdun RE, Karlseder J,. Replication and protection of telomeres. Nature 2007; 447: 924-931.
25. Cosme-Blanco W, Shen MF, Lazar AJ, et al,. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007; 8: 497-503.
26. Uziel O, Beery E, Dronichev V, et al,. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One 2010; 5: e9132.
27. Zhang X, Mar V, Zhou W, et al,. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-2399.
28. Eriksson D, Lofroth PO, Johansson L, et al,. Cell cycle disturbances and mitotic catastrophes in HeLa Hep2 cells following 2.5 to 10 Gy of ionizing RT. Clin Cancer Res 2007; 13: 5501s-5508s.
29. Eriksson D, Stigbrand T,. RT-induced cell death mechanisms. Tumour Biol 2010; 31: 363-372.
30. Roninson IB, Broude EV, Chang BD,. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4: 303-313.
31. Huang X, Tran T, Zhang L, et al,. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005; 102: 1065-1070.
32. Ianzini F, Kosmacek EA, Nelson ES, et al,. Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following RT-induced mitotic catastrophe. Cancer Res 2009; 69: 2296-2304.
33. Zhong FL, Batista LF, Freund A, et al,. TPP1 OB-fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell 2012; 150: 481-494.